UNSPSC 51286102: Hexedine

This classification denotes a topical anti-infective agent with the molecular formula C22H45N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LRE2528Y9E, chemically known as 2,6-bis(2-ethylhexyl)-hexahydro-7a-methyl-1h-imidazo(1,5-c)imidazole but more generally known as hexedine, which bears US NIH Compound Identifier 22291. European Medicines Agency schedules Hexedine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08035MIG. The term HEXEDINE is an International Non-Proprietary Name.

HEXEDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: N12C(CN(C1)CC(CCCC)CC)(CN(C2)CC(CCCC)CC)C.

UNSPSC 51286102 Hexedine (Commodity) covers pharmaceutical active ingredients and their precursors for use in hospital, clinic, and public health supply chains, though recent state and local solicitations under this code show limited direct activity. The available opportunities reflect pharmaceutical warehouse piggyback contracts and community health procurement tied to opioid response, rather than hexedine itself—state and local buyers under this code tier are acquiring antibiotic powders (Doxycycline Hyclate, Ciprofloxacin Hydrochloride) and naloxone through established cooperative purchasing vehicles and direct competitive bidding. Issuing bodies include state health departments and county health authorities procuring for emergency preparedness, disease control, and overdose-reversal programs; these purchases flow through intermediaries such as MMCAP Infuse consortiums and pharmaceutical warehouse brokers.

Geographic activity centers on Illinois and Florida based on the most recent posted opportunities. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026 under Bid Number 26-482DPH-PREPD-B-53392 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets totaling $2,999,999.11 across twelve months plus two renewal years; this was a completed Invitation for Bid, not an open solicitation. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county community health building; the response deadline was July 26, 2026. Code activity appears sparse and commodity-specific rather than reflecting broad-spectrum hexedine procurement at the state and local level.